Volume 4.29 | Aug 5 - Cancer Stem Cell News

Cancer Stem Cell News 4.29 August 5, 2015

TOP STORY

An Apoptosis-Enhancing Drug Overcomes Platinum Resistance in a Tumor-Initiating Subpopulation of Ovarian Cancer
Researchers showed that 16 independent primary high-grade serous ovarian cancers samples contained a CA125-negative population enriched for carboplatin-resistant cancer initiating cells. While treatment with carboplatin enriched for CA125-negative cells, co-treatment with carboplatin and birinapant eliminated these cells in high-grade serous ovarian cancers expressing high levels of the inhibitor of apoptosis protein cIAP in the CA125-negative population. [Nat Commun] Full Article

Culture and Characterize Human Mammary Epithelial Progenitors with Serum-Free EpiCult-B (Human) Free Protocols

PUBLICATIONS (Ranked by impact factor of the journal)

Chemotherapy Triggers HIF-1-Dependent Glutathione Synthesis and Copper Chelation that Induces the Breast Cancer Stem Cell Phenotype
Scientists demonstrated that chemotherapy induces the expression of the cystine transporter xCT and the regulatory subunit of glutamate-cysteine ligase in a hypoxia-inducible factor (HIF)-1–dependent manner, leading to increased intracellular glutathione levels, which inhibit mitogen-activated protein kinase kinase activity through copper chelation. [Proc Natl Acad Sci USA] Abstract

Ceacam1L Modulates STAT3 Signaling to Control the Proliferation of Glioblastoma-Initiating Cells
Researchers demonstrated that carcinoembryonic antigen-related cell adhesion molecule Ceacam1L acts as a crucial factor in glioblastoma-initiating cells maintenance and tumorigenesis by activating c-Src/STAT3 signaling. [Cancer Res] Abstract

Cytomegalovirus Immediate-Early Proteins Promote Stemness Properties in Glioblastoma
Investigators showed how human cytomegalovirus immediate-early proteins are preferentially expressed in glioma stem-like cells where they colocalize with the other glioblastoma stemness markers, CD133, Nestin, and Sox2. [Cancer Res] Abstract

Fluorescent CSC Models Evidence that Targeted Nanomedicines Improve Treatment Sensitivity of Breast and Colon Cancer Stem Cells
Researchers developed a novel in vitro fluorescent cancer stem cell (CSC) model that allowed them to visualize these cells in heterogeneous population and to monitor CSC biological performance after therapy. [Nanomedicine] Abstract | Graphical Abstract

USP44⁺ Cancer Stem Cells Subclones Contributed to Breast Cancer Aggressiveness by Promoting Vasculogenic Mimicry
Breast cancer stem cells (CSCs) presented the centrosome amplification phenotype and ubiquitin-specific protease 44 (USP44) upregulation. USP44 expression contributed to the establishment of bipolar spindles in breast CSCs with supernumerary centrosomes by localizing at pole-associated centrosomes. [Mol Cancer Ther] Abstract

Heat Shock Factor 1 Induces Cancer Stem Cell Phenotype in Breast Cancer Cell Lines
Researchers explored whether high heat shock factor 1 (HSF1) expression might be associated with the cancer stem cell (CSC) phenotype. They also evaluated the effects of HSF1 over-expression and knock-down on sphere formation and CSC marker expression in breast cancer cell lines. [Breast Cancer Res Treat] Full Article

4-Acetylantroquinonol B Inhibits Colorectal Cancer Tumorigenesis and Suppresses Cancer Stem-Like Phenotype.
Researchers hypothesized that 4-acetylantroquinonol B (4-AAQB) may play an active role in the suppression of cellular transformation, tumor aggression and progression, as well as chemoresistance in colorectal carcinoma. They investigated the antiproliferative role of 4-AAQB and its underlying molecular mechanism. [Toxicol Appl Pharmacol] Abstract

Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells
Scientists determined whether the small leucine-rich proteoglycans decorin and lumican are recruited in cell plasticity and microenvironmental adaptation of differentiated cancer cells induced towards stem-like phenotype. [PLoS One] Full Article

JNK Is Required for Maintaining the Tumor-Initiating Cell-Like Properties of Acquired Chemoresistant Human Cancer Cells
Investigators determined the impact of c-Jun N-terminal kinase (JNK) on the tumor-initiating cell-like properties of acquired chemoresistant human cancer cells. [Acta Pharmacol Sin] Abstract

Upregulation of miR-130b Enhances Stem Cell-Like Phenotype in Glioblastoma by Inactivating the Hippo Signaling Pathway
Investigators report that miR-130b directly repressed MST1 and SAV1 expression in human glioblastoma cells. Overexpression of miR-130b induced hyperactivation of the YAP/TAZ and enhanced expression of the Hippo signaling downstream genes CTGF and the pluripotency associated markers, including CD133, SOX2, Nanog, MYC and BMI1, leading to promotion of glioblastoma stem cell phenotype. [Biochem Biophys Res Commun] Abstract

[Watch the Video] Detect Cancer Stem Cells with ALDEFLUOR™.

REVIEWS

The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis
The authors present a detailed comparison of all renal cancer stem cell-like populations identified by now as well as their presumable origin. They also discuss current knowledge of hypoxia-inducible factor (HIF)-1α/2α signaling pathways in the promotion of undifferentiated tumor phenotype in general, including some experimental findings specific for pseudo-hypoxic clear-cell renal cell carcinoma, mostly dependent from HIF-2α oncogenic functions. [Stem Cell Rev Rep] Full Article

Novel Small Molecule Inhibitors of Cancer Stem Cell Signaling Pathways
The development of novel chemotherapeutic agents and proteins specifically targeting cancer stem cells are attractive pharmaceutical candidates. The authors describe small molecule inhibitors of stem cell pathways Wnt, Notch and Hedgehog, and their recent chemotherapy clinical trials. [Stem Cell Rev] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

INDUSTRY NEWS

Moffitt Cancer Center Teams Up with MD Anderson to Discover, Test Novel Agents to Prevent Cancer
Moffitt Cancer Center has joined MD Anderson’s National Cancer Institute (NCI) Phase 0/I/II Cancer Prevention Clinical Chemoprevention Trials Consortia. Sponsored by the NCI’s Division of Cancer Prevention, the consortia conducts early clinical development of promising new preventive agents through its Phase 0/I/II Cancer Prevention Clinical Trials Program. [Moffitt Cancer Center (Newswise, Inc.)] Press Release

Eisai’s In-House Developed Novel Anticancer Agent Lenvima^® Receives Breakthrough Therapy Designation from U.S. FDA for Renal Cell Carcinoma
Eisai Co., Ltd. announced its U.S. subsidiary Eisai Inc. has received a breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for its in-house developed novel anticancer agent Lenvima^® (lenvatinib mesylate, “lenvatinib”) for the potential indication of advanced and/or metastatic renal cell carcinoma. [Eisai Co., Ltd.] Press Release

From our sponsor: Learn about detecting cancer stem cells with ALDEFLUOR™. Watch the webinar.

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW ISCBC 2015: International Stem Cell Biology Conference
October 11-12, 2015
Osaka, Japan

Visit our events page to see a complete list of events in the cancer stem cell community.

JOB OPPORTUNITIES

NEW Research Associate – Prostate Cancer (Imperial College London)

NEW Postdoctoral Position – Experimental Oncology/Stem Cell Biology (Academia Medical Center)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Research Fellow – Cancer Research (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellowship – Brain Tumor Biology and Stem Cells (Universität Basel)

Postdoctoral Fellow – Cancer Research (National University of Singapore)

Postdoctoral Cancer Research – Molecular Targets for Tumor Therapy (University of Würzburg)

Higher Scientific Officer – Cancer Proteomics (Institute of Cancer Research)

Postdoctoral Positions- Cancer Research (Rutgers University)

Postdoctoral Research Associate – Breast Stem Cell Biology (University of Miami Miller School of Medicine)

Postdoctoral Fellowships – Cancer Research (German Cancer Research Center)

Professor – Cancer Stem Cells (Dalian Medical University)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here

Learn more about Cancer Stem Cell News: Archives | Events | Contact Us